【缺藥訊息】 公告日期：2024/6/14。 缺藥品項：Taflotan-S 單支裝眼藥水。 缺藥原因：因工廠生產問題導致缺藥。 替代藥品：院內有同類替代藥。 配套措施：剩餘量保留慢性處方箋使用，請改用院內其他品項替代。

Elevated intraocular pressure: Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Tafluprost acid is a fluorinated prostaglandin F2-alpha analog believed to reduce intraocular pressure by increasing outflow of aqueous humor via the uveoscleral pathway; exact mechanism by which it reduces IOP is unknown.

"Onset of action: Reduction of intraocular pressure (IOP): 2 to 4 hours
Peak effect: Maximum reduction of IOP: ~12 hours
Absorption: Through the cornea
Metabolism: Ester prodrug (tafluprost) is hydrolyzed to the biologically active acid metabolite (tafluprost acid); tafluprost acid metabolized further via fatty acid beta oxidation and phase II conjugation
Time to peak, plasma: ~10 minutes
"

There are no contraindications listed in the manufacturer’s prescribing information.

"C(FDA)
Adverse events have been observed in animal reproduction studies. Effective contraception during treatment is recommended for women of childbearing potential."

It is not known if tafluprost is excreted in breast milk. The manufacturer recommends that caution be exercised when administering tafluprost to breast-feeding women.

"Ophthalmic: Conjunctival hyperemia (4% to 20%)
Central nervous system: Headache (6%)"

"Elevated intraocular pressure:
Ophthalmic: One drop in the affected eye(s) once daily in the evening; do not exceed the once daily dosage because it has been shown that more frequent administration may decrease the IOP-lowering effect"

There are no dosage adjustments provided in the manufacturer’s labeling.

There are no dosage adjustments provided in the manufacturer’s labeling.